The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

16 articles for ZF Tao


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.EBI
Abbvie
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.EBI
Abbvie
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.EBI
Genentech
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.EBI
Abbott Laboratories
Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors.EBI
Abbott Laboratories
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.EBI
Abbvie
Synthesis and in-vitro biological activity of macrocyclic urea Chk1 inhibitors.EBI
Abbott Laboratories
Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: improving oral biovailability.EBI
Abbott Laboratories
Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.EBI
Abbott Laboratories
Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.EBI
Abbott Laboratories
1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: extended exploration on phenyl ring substitutions and preliminary ADME/PK studies.EBI
Abbott Laboratories
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XEBI
Abbvie
Structure-Based Design of A-1293102, a Potent and Selective BCL-XEBI
Abbvie
Imidazopyridazine derivatives as PI3KB inhibitorsBDB
Janssen Pharmaceutica
Metalloenzyme inhibitor compoundsBDB
Viamet Pharmaceuticals (Bermuda)
5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa.BDB
Bristol-Myers Squibb Pharmaceutical Research Institute